Skip to content

Continuous Wireless Ultrasound to Monitor Fetal Health

Continuous Wireless Ultrasound to Monitor Fetal Health

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07676474
Enrollment
50
Registered
2026-06-30
Start date
2026-06-30
Completion date
2028-06-30
Last updated
2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant Woman With Single Pregnancy, Ultrasound Fetal Medicine

Keywords

Ultrasound, Fetal Ultrasound, Investigational Device, Pregnancy, Singleton, Single pregnancy

Brief summary

This study is a single-center, prospective, and non-randomized feasibility study designed to evaluate the practicality, tolerability, and data quality of short-duration continuous fetal monitoring using a wireless bioadhesive ultrasound device. The study involves a single visit per participant and does not include any therapeutic intervention. Eligible participants will undergo placement of a wireless bioadhesive ultrasound (ABAUS) device on the maternal abdomen for a short-duration monitoring session. The device will acquire continuous or semi-continuous ultrasound data for a total of 10-30 minutes per participant, without altering standard clinical care. The study is observational and is intended to assess the technical feasibility of device placement, the stability of the coupling during routine maternal movement, image quality over time, and the ability to monitor fetal motion, heart rate, and uterine activity using the investigational device under controlled yet realistic clinical conditions. The study is non-interventional. No diagnostic or therapeutic decisions will be made based on the ultrasound data collected as part of this research protocol, and all standard prenatal care will proceed independently of participation in this study.

Interventions

DEVICEWireless Ultrasound Device

Participants will undergo placement of the investigational wireless bio-adhesive ultrasound (ABAUS) device on the maternal abdomen. This device constitutes the sole study-related exposure. The device will be externally applied to intact abdominal skin using a skin-safe bio-adhesive and used to acquire continuous or semi-continuous ultrasound data for approximately 10-30 minutes.

Sponsors

Boston Children's Hospital
Lead SponsorOTHER
Massachusetts Institute of Technology
CollaboratorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Pregnant individual 18 years or older 2. Singleton uterine pregnancy 3. Gestational age 20 to 39 gestational weeks 4. Able to provide written informed consent 5. Willing to go an single visit lasting 45 minutes - 1 hour including device placement, monitoring and removal 6. Willing to permit placement of the wireless bioadhesive ultrasound device on their abdomen for approximately 10-30 minutes

Exclusion criteria

1. Multiple gestation 2. Maternal abdominal skin condition at the potential site of attachment, such as rash, open wound, etc., preventing placement 3. Known allergy or hypersensitivity to adhesive material or hydrogel products 4. Need for urgent clinical management/triage 5. BMI \> 35, as the signal quality could be impacted by BMI and not the device specifically

Design outcomes

Primary

MeasureTime frameDescription
Successful continuous abdominal imaging over a defined monitoring interval10-30 minutesAcquisition of fetal ultrasound imaging data over a 10-30 minute period
Number of skin adverse events30 - 60 minutesThe number of participants experiencing adverse effects, discomfort, or skin irritation related to the device will be recorded.

Countries

United States

Contacts

CONTACTFetal Imaging Research Team
FetalImaging@childrens.harvard.edu(617) 919-5088
PRINCIPAL_INVESTIGATOREllen Grant, MD

Boston Children's Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026